NCT02932878

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Sun Pharmaceutical Industries, Inc. · Industry
• Sex: All
• Age: 2 Years – 18 Years
• Healthy volunteers: Accepted

Summary

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis

Detailed description

To evaluate the potential of DSXS to suppress HPA axis function in patients with mild to moderate plaque psoriasis. To evaluate the efficacy parameters and adverse event (AE) profile of DSXS administered to patients with mild to moderate plaque psoriasis.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	DSXS topical	topical treatment

Timeline

• Start date: 2016-09-02
• Primary completion: 2017-04-10
• Completion: 2017-10-16
• First posted: 2016-10-13
• Last updated: 2018-12-06
• Results posted: 2018-12-06

Locations

1 site across 1 country: United States